December 18, 2025 10:52 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Worst is over,’ says IndiGo CEO after flight chaos; staff told to ignore speculation | Chaos at Hyderabad's Lulu Mall! Nidhhi Agerwal swarmed by fans, police register case | TCS bets big on AI, shares spike as company reveals ambitious plan | Delhi goes into emergency mode! Work from home, vehicle bans as AQI hits ‘severe’ | Massive fire guts shanties near Eco Park in Kolkata; no casualties | Indian Visa Application Centre in Dhaka shuts down early amid rising security concerns | Market update: Sensex tumbles 120 points, Nifty below 25,850 at closing bell | ‘Won’t apologise’: Prithviraj Chavan stands firm on controversial Operation Sindoor remark despite backlash | India summons Bangladesh High Commissioner after provocative 'seven sisters' remark | Amazon eyes $10 billion investment in OpenAI — a gamechanger for AI industry!
COVAXIN

Fight against COVID-19: Third phase of human trial of Covaxin to commence soon in IMS- SUM Hospital

| @indiablooms | Oct 27, 2020, at 07:59 pm

Bhubaneswar/UNI: The third phase of the human trial of COVAXIN, the much-awaited indigenous vaccine being developed against Covid-19, will commence at the Institute of Medical Sciences and SUM Hospital here soon.

As the number of cases and deaths due to Covid- 19 continues to rise across the country, the battle against the disease through the search for a suitable vaccine has almost come to the final stage, Dr E. Venkata Rao, Principal Investigator in the COVAXIN human trial said.

Dr.Rao, a Professor in the Department of Community Medicine at IMS and SUM Hospital, said IMS and SUM Hospital is in the list of 21 medical institutes selected across the country by the Indian Council for Medical Research (ICMR) where the third phase trial would be conducted.

Sum Hospital is the only institute in Odisha which has been selected for the trial.

The indigenous vaccine, being developed by ICMR and Bharat Biotech, has received the approval of the Central Drugs Standard Control Organisation (CDSCO) for initiating the third phase trial.

Dr.Rao said after completion of the first and second phase of the trial with demonstrable safety profile and immunogenicity, the large scale efficacy trial involving thousands of volunteers has been planned

Dr Rao, who is the head of the Preventive and Therapeutic Clinical Trial Unit (PTCTU) at IMS and SUM Hospital, said during this phase the age limit and eligibility/ screening criteria would be relaxed and several volunteers who are otherwise apparently healthy would be recruited for the trial.

Like the previous phases, half of the volunteers would receive placebo and the remaining half would be administered COVAXIN in this phase.

Even health care workers would be recruited for the trial. The volunteers would be followed up over a considerable period of time to look at the efficacy of the vaccine in preventing the development of the Corona disease.

He said there had been a huge response and enthusiasm among people who had offered themselves to be volunteers for the trial.

The interested volunteers for the project could enroll themselves for the trial by registering online at www.ptctu.soa.ac under the section register for clinical trials, Dr Rao said. 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.